| Literature DB >> 24723944 |
Ke-Wei Meng1, Mei Dong1, Wei-Guo Zhang1, Qing-Xian Huang1.
Abstract
Objectives. Bile duct invasion (BDI) is a rare event in hepatocellular carcinoma (HCC). The present study aimed at investigating clinical characteristics and surgical outcome of HCC patients with bile duct invasion. Methods. 413 patients with HCC undergoing curative surgery were divided into two groups with (B(+)) and without BDI (B(-)). BDI was further classified as central type (B1) and peripheral type (B2). Survival was compared, and risk factors affecting prognosis were identified. Results. 35 (8.5%) patients were diagnosed BDI. Total bilirubin was significantly higher in B(+) group than in B(-) group (P < 0.001). Multiple lesions and large nodules (>5 cm) were predominantly identified in B(+) group (P < 0.01, resp.). Portal vein invasion was more frequently observed in B(+) than in B(-) group (P = 0.003). Univariate and multivariate analyses identified central BDI as a significant factor affecting prognosis of HCC patients (risk 1.3, 95% CI 1.1-2.2, P = 0.015). The gross overall survival of patients in B(+) was significantly worse than in B(-) (P = 0.001), which, however, was not different between B2 and B(-) (P > 0.05). Conclusions. Central but not peripheral BDI was associated with poorer prognosis of HCC patients. Curative surgical resection of tumors and invaded bile duct supplies the only hope for long-term survival of patients.Entities:
Year: 2014 PMID: 24723944 PMCID: PMC3958710 DOI: 10.1155/2014/604971
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Preoperative clinical variables of HCC patients with and without bile duct invasion.
| Clinical parameters | Bile duct invasion |
| |||
|---|---|---|---|---|---|
| Yes ( | No ( | ||||
| Number or mean | % or SE | Number or mean | % or SE | ||
| Age (y) | 51.3 | 2.0 | 50.2 | 0.6 | 0.571 |
| Gender | |||||
| Male/female | 24/11 | 68.6/31.4 | 309/69 | 81.7/18.3 | 0.073 |
| Virus status | |||||
| HBV/HCV/none | 26/0/9 | 74.3/0/25.7 | 286/7/85 | 75.7/1.9/22.5 | 0.669 |
| Child-Pugh classification | |||||
| A/B | 25/10 | 71.4/28.6 | 276/102 | 73.0/27.0 | 0.839 |
| Liver cirrhosis | 25 | 71.4 | 247 | 65.3 | 0.577 |
| Hemoglobin (g/L) | 130.5 | 4.9 | 128.8 | 1.7 | 0.752 |
| Platelet count (×109/L) | 122.1 | 6.6 | 113.9 | 3.2 | 0.439 |
| TBIL (umol/L) | 54.0 | 19.0 | 22.5 | 1.7 |
|
| ALT (U/L) | 83.9 | 22.9 | 62.5 | 3.4 | 0.102 |
| AST (U/L) | 83.5 | 22.9 | 61.6 | 3.0 | 0.070 |
| ALB (g/L) | 38.3 | 0.9 | 38.9 | 0.3 | 0.485 |
| PT (s) | 13.2 | 0.4 | 13.5 | 0.1 | 0.360 |
| AFP (ng/mL) | 5770.7 | 2424.0 | 4071.2 | 1022.5 | 0.622 |
HCC: hepatocellular carcinoma; SE: standard error; HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: alpha-fetoprotein; TBIL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALB: albumin; PT: prothrombin time.
The bold value means “P < 0.05” or “statistically different”.
Pathological and surgical parameters of HCC patients with and without bile duct invasion.
| Tumor status parameters | Bile duct invasion |
| |||
|---|---|---|---|---|---|
| Yes ( | No ( | ||||
| Number or mean | % or SE | Number or mean | % or SE | ||
| Tumor number | |||||
| Single/multiple | 20/15 | 57.1/42.9 | 297/81 | 78.6/21.4 |
|
| Maximal tumor size | |||||
| ≤5 cm/>5 cm | 11/24 | 31.4/68.6 | 216/162 | 57.1/42.9 |
|
| Capsule formation | |||||
| Present/absent | 11/24 | 31.4/68.6 | 116/262 | 30.7/69.3 | 1.000 |
| Portal vein invasion | |||||
| Positive/negative | 10/25 | 28.6/71.4 | 38/340 | 10.1/89.9 |
|
| Cellular differentiation | |||||
| Well/moderately/poorly | 3/22/10 | 8.6/62.9/28.5 | 25/252/101 | 6.1/64.2/29.7 | 0.864 |
| Surgical mode | |||||
| Nonanatomic/anatomic | 26/9 | 74.3/26.7 | 239/139 | 63.2/36.8 | 0.215 |
| Surgical margin | |||||
| <1 cm/≥1 cm | 23/12 | 65.7/34.3 | 175/203 | 46.3/53.7 |
|
| Intraoperative blood transfusion (mL) | 602.9 | 87.4 | 658.7 | 23.4 | 0.493 |
| Operation time (h) | 5.6 | 1.2 | 4.2 | 0.5 | 0.128 |
| Postoperative morbidity | |||||
| Presence/absence | 9/26 | 25.7/74.3 | 135/243 | 35.7/64.3 | 0.235 |
| Hospital stay (d) | 24.6 | 1.6 | 23.6 | 0.8 | 0.683 |
HCC: hepatocellular carcinoma; SE: standard error.
The bold value means “P < 0.05” or “statistically different”.
Figure 1Kaplan-Meier curves of overall survival of hepatocellular carcinoma patients with bile duct invasion (B+ group, n = 35) and without bile duct invasion (B− group, n = 378).
Figure 2Kaplan-Meier curves of overall survival of the 35 patients with bile duct invasion according to different type of bile duct invasion. B1, central type; B2, peripheral type.
Univariate analysis of risk factors for prognosis of HCC after surgical resection.
| Variables |
| Median survival (m) |
|
|---|---|---|---|
| Age (≤40/>40 yr) | 96/317 | 28.4/30.6 | 0.475 |
| Gender (male/female) | 333/80 | 30.4/28.3 | 0.423 |
| Virus status | |||
| HBV/HCV/none | 312/7/94 | 32.0/30.2/29.5 | 0.210 |
| Child-Pugh classification | |||
| A/B | 301/112 | 33.6/30.0 | 0.456 |
| Liver cirrhosis (+/−) | 272/141 | 29.3/31.4 | 0.512 |
| Hemoglobin (<110/≥110 g/L) | 62/351 | 32.7/34.3 | 0.666 |
| Platelet count (×109/L) (<100/≥100) | 194/219 | 33.1/27.3 |
|
| ALT (≤40/>40 U/L) | 195/218 | 33.5/27.4 |
|
| AST (≤40/>40 U/L) | 139/274 | 37.9/26.3 |
|
| TBIL (≤17.1/>17.1 umol/L) | 228/185 | 29.6/30.4 | 0.870 |
| Albumin(<35/≥35 g/L) | 320/93 | 31.3/27.0 | 0.153 |
| PT (<14/≥14 s) | 278/135 | 29.6/31.0 | 0.580 |
| AFP (<20/≥20 ng/mL) | 118/295 | 37.3/27.2 |
|
| Tumor size (<5/≥5 cm) | 227/186 | 37.2/21.4 |
|
| tumor number (1/≥2) | 317/96 | 33.3/19.2 |
|
| Capsule formation (+/−) | 286/127 | 33.7/21.8 |
|
| Bile duct invasion (B−/B1/B2) | 378/28/7 | 31.1/14.6/39.0 |
|
| Portal vein invasion (+/−) | 48/365 | 14.6/32.2 |
|
| Surgical margin (<1/≥1 cm) | 198/215 | 31.9/28.7 | 0.153 |
| Blood transfusion (≤600/>600 mL) | 196/217 | 36.7/24.4 |
|
Hepatocellular carcinoma; HBV: hepatitis B virus, AFP: alpha-fetoprotein, TBIL: total bilirubin, ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALB: albumin; PT: prothrombin time.
The bold value means “P < 0.05” or “statistically different”.
Multivariate analysis of risk factors for prognosis of HCC after surgical resection.
| Variables | Hazard ratio | 95% CI |
|
|---|---|---|---|
| Tumor size (≥5 cm) | 1.7 | 1.3–2.2 | <0.001 |
| Tumor number (≥2) | 1.6 | 1.2–2.1 | <0.001 |
| Capsule absence | 2.0 | 1.5–2.6 | <0.001 |
| Bile duct invasion (B1) | 1.3 | 1.1–1.7 | 0.015 |
| Portal vein invasion | 1.5 | 1.1–2.2 | 0.015 |
| Blood transfusion (>600 mL) | 1.7 | 1.3–2.2 | <0.001 |
| ALT (>40 U/L) | 0.9 | 0.7–1.2 | 0.851 |
| AST (>40 U/L) | 1.7 | 1.3–2.3 | <0.001 |
| Platelet count (×109/L) (<100) | 0.9 | 0.7–1.2 | 0.428 |
| AFP (≥20 ng/mL) | 1.6 | 1.2–2.1 | 0.002 |
HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PT: prothrombin time; AFP: alpha-fetoprotein.
Summary of the previous reports of surgical outcome of HCC with bile duct invasion.
| Authors | Year | Number of HCC patients with bile duct invasion (percentage) | Overall survival |
|---|---|---|---|
| Satoh et al. [ | 2000 | 17 (2.5%) | Similar to HCC without bile duct thrombus ( |
| Shiomi et al. [ | 2001 | 17 (12.9%) | Similar to HCC without bile duct thrombus ( |
| Yeh et al. [ | 2004 | 17 (3.0%) | Worse than HCC without bile duct thrombus ( |
| Qin et al. [ | 2004 | 34 (0.8%) | NA |
| Ikenaga et al. [ | 2009 | 15 (5.5%) | Worse than HCC without bile duct invasion ( |
| Yu et al. [ | 2011 | 20 (3.0%) | Worse than HCC without bile duct thrombus ( |
| Our series | 35 (8.5%) | Worse than HCC without bile duct invasion ( |